ME Therapeutics Holdings Inc.
METX
CNSX
| 11/30/2025 | 08/31/2025 | 05/31/2025 | 02/28/2025 | 11/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 2.84% | 9.80% | 17.06% | 81.40% | 81.76% |
| Total Depreciation and Amortization | 834.21% | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -95.45% | -74.11% | -56.71% | -89.84% | -90.00% |
| Change in Net Operating Assets | 23.63% | 203.96% | 79.65% | 69.47% | 177.59% |
| Cash from Operations | -88.46% | -27.85% | -22.14% | -2.85% | -1.76% |
| Capital Expenditure | -2,204.69% | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -417.72% | -- | -- | -- | -- |
| Cash from Investing | -1,217.48% | -- | -- | -121.84% | -102.56% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -44.27% | -35.75% | 5.00% | 45.75% | -- |
| Issuance of Common Stock | -20.64% | -32.48% | -37.14% | 22.90% | 1,246.32% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -26.47% | -37.82% | -42.03% | 18.60% | 1,184.20% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -115.99% | -119.57% | -102.13% | -53.74% | 173.64% |